Journal
EXPERT REVIEW OF NEUROTHERAPEUTICS
Volume 10, Issue 8, Pages 1347-1359Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1586/ERN.10.93
Keywords
cognitive-behavioral therapy; early intervention; olanzapine; omega-3 fatty acids; prodrome; psychosis; risperidone; ultra-high risk; ziprasidone
Categories
Funding
- National Institute of Mental Health
- Pfizer
Ask authors/readers for more resources
During recent decades, interest in the prevention of mental illnesses has increased. Improved diagnostic tools, the advent of atypical antipsychotic medications and the development of phase-specific psychosocial treatments have made intervention research in people at ultra-high risk for developing schizophrenia or a related psychotic disorder possible. Preliminary data suggest that low doses of atypical antipsychotic medications augmented by psychosocial treatments may delay the onset of psychosis in some individuals. Findings support further research for the establishment of best-practice standards.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available